Skip to main content
Fig. 5 | Diabetology & Metabolic Syndrome

Fig. 5

From: Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis

Fig. 5

Meta-analysis of finerenone and GLP1-RA trials on renal end points. (A) Meta-analysis of finerenone and GLP1-RA trials on a broad kidney end point stratified by drug class. (B) Meta-analysis of finerenone and GLP1-RA trials on a narrower kidney outcome excluding macroalbuminuria stratified by drug class

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us